-
Je něco špatně v tomto záznamu ?
The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer
K. Liu, R. Nicoletti, H. Zhao, X. Chen, PK. Chiu, CF. Ng, R. Pichler, LS. Mertens, T. Yanagisawa, L. Afferi, A. Mari, S. Katayama, JG. Rivas, R. Campi, MC. Mir, M. Rink, Y. Lotan, M. Rouprêt, SF. Shariat, JY. Teoh
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
Grantová podpora
8601521
University Grants Committee (UGC) Research Matching Fund
14117421
General Research Fund/Early Career Scheme of the Research Grants Council, Hong Kong
PubMed
39257199
DOI
10.1111/bju.16493
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- aplikace intravezikální MeSH
- BCG vakcína * terapeutické užití MeSH
- invazivní růst nádoru MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory močového měchýře neinvadující svalovinu MeSH
- nádory močového měchýře * farmakoterapie patologie mortalita MeSH
- retrospektivní studie MeSH
- senioři MeSH
- statiny * terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy. PATIENTS AND METHODS: A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression. RESULTS: A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013). CONCLUSIONS: Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.
Department of Experimental and Clinical Biomedical Science University of Florence Florence Italy
Department of Experimental and Clinical Medicine University of Florence Florence Italy
Department of Urology 2nd Faculty of Medicine Charles University Prague Czechia
Department of Urology Hospital Clinico San Carlos Madrid Spain
Department of Urology Hospital Universitario La Ribera Valencia Spain
Department of Urology Luzerner Kantonsspital Lucerne Switzerland
Department of Urology Marienkrankenhaus Hamburg gGmbH Hamburg Germany
Department of Urology Medical University of Innsbruck Innsbruck Austria
Department of Urology Medical University of Vienna Vienna Austria
Department of Urology The Jikei University School of Medicine Tokyo Japan
Department of Urology University of Texas Southwestern Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25002932
- 003
- CZ-PrNML
- 005
- 20250206103946.0
- 007
- ta
- 008
- 250121s2025 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bju.16493 $2 doi
- 035 __
- $a (PubMed)39257199
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Liu, Kang $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000179296534
- 245 14
- $a The potential benefits of concomitant statins treatment in patients with non-muscle-invasive bladder cancer / $c K. Liu, R. Nicoletti, H. Zhao, X. Chen, PK. Chiu, CF. Ng, R. Pichler, LS. Mertens, T. Yanagisawa, L. Afferi, A. Mari, S. Katayama, JG. Rivas, R. Campi, MC. Mir, M. Rink, Y. Lotan, M. Rouprêt, SF. Shariat, JY. Teoh
- 520 9_
- $a OBJECTIVE: To investigate the influence of statins on the survival outcomes of patients with non-muscle-invasive bladder cancer (NMIBC) treated with adjuvant intravesical bacille Calmette-Guérin (BCG) immunotherapy. PATIENTS AND METHODS: A retrospective cohort of consecutive patients with NMIBC who received intravesical BCG therapy from 2001 to 2020 and statins prescription were identified. Overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) were analysed between the Statins Group vs No-Statins Group using Kaplan-Meier method and multivariable Cox regression. RESULTS: A total of 2602 patients with NMIBC who received intravesical BCG were identified. The median follow-up was 11.0 years. On Kaplan-Meier analysis, the Statins Group had significant better OS (P < 0.001), CSS (P < 0.001), and PFS (P < 0.001). Subgroup analysis indicated statins treatment started before BCG treatment had better CSS (P = 0.02) and PFS (P < 0.01). Upon multivariable Cox regression analysis, the 'statins before BCG' group was an independent protective factor for OS (hazard ratio [HR] 0.607, 95% confidence interval [CI] 0.514-0.716), and CSS (HR 0.571, 95% CI 0.376-0.868), but not RFS (HR 0.885, 95% CI 0.736-1.065), and PFS (HR 0.689, 95% CI 0.469-1.013). CONCLUSIONS: Statins treatment appears to offer protective effects on OS and CSS for patients with NMIBC receiving adjuvant intravesical BCG.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a nádory močového měchýře $x farmakoterapie $x patologie $x mortalita $7 D001749
- 650 12
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 12
- $a BCG vakcína $x terapeutické užití $7 D001500
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a aplikace intravezikální $7 D000283
- 650 _2
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 _2
- $a invazivní růst nádoru $7 D009361
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a nádory močového měchýře neinvadující svalovinu $7 D000093284
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Nicoletti, Rossella $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China $u Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy
- 700 1_
- $a Zhao, Hongda $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000324141484
- 700 1_
- $a Chen, Xuan $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Chiu, Peter Ka-Fung $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China $1 https://orcid.org/0000000214998372
- 700 1_
- $a Ng, Chi-Fai $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Pichler, Renate $u Department of Urology, Medical University of Innsbruck, Innsbruck, Austria $1 https://orcid.org/0000000152869048
- 700 1_
- $a Mertens, Laura S $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo, Japan $1 https://orcid.org/0000000274100712
- 700 1_
- $a Afferi, Luca $u Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland $1 https://orcid.org/0000000254721933
- 700 1_
- $a Mari, Andrea $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy $1 https://orcid.org/0000000190705706
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan $1 https://orcid.org/0000000283772457
- 700 1_
- $a Rivas, Juan Gomez $u Department of Urology, Hospital Clinico San Carlos, Madrid, Spain $1 https://orcid.org/0000000205563035
- 700 1_
- $a Campi, Riccardo $u Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy $u Unit of Urological Robotic Surgery and Renal Transplantation, Careggi Hospital, University of Florence, Florence, Italy $u European Association of Urology Young Academic Urologists Renal Cancer Working Group, Arnhem, The Netherlands $1 https://orcid.org/0000000152370888
- 700 1_
- $a Mir, Maria Carmen $u Department of Urology, Hospital Universitario La Ribera, Valencia, Spain $1 https://orcid.org/0000000213911378
- 700 1_
- $a Rink, Michael $u Department of Urology, Marienkrankenhaus Hamburg gGmbH, Hamburg, Germany
- 700 1_
- $a Lotan, Yair $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $1 https://orcid.org/0000000156922723
- 700 1_
- $a Rouprêt, Morgan $u Department of Urology, GRC 5 Predictive Onco-Urology, AP-HP, Hôpital Pitié-Salpêtrière, Sorbonne Université, Paris, France
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria $u Department of Urology, University of Texas Southwestern, Dallas, TX, USA $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Teoh, Jeremy Yuen-Chun $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China $u Department of Urology, Medical University of Vienna, Vienna, Austria $u European Association of Urology - Young Academic Urologists Urothelial Carcinoma Working Group, Arnhem, Netherlands $1 https://orcid.org/0000000293612342
- 773 0_
- $w MED00011371 $t BJU international $x 1464-410X $g Roč. 135, č. 1 (2025), s. 88-94
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39257199 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206103941 $b ABA008
- 999 __
- $a ok $b bmc $g 2262993 $s 1238939
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 135 $c 1 $d 88-94 $e 20240910 $i 1464-410X $m BJU international $n BJU Int $x MED00011371
- GRA __
- $a 8601521 $p University Grants Committee (UGC) Research Matching Fund
- GRA __
- $a 14117421 $p General Research Fund/Early Career Scheme of the Research Grants Council, Hong Kong
- LZP __
- $a Pubmed-20250121
